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1. Introduction  
Over the last decades, several studies have demonstrated that cancer cells have a unique 
metabolism compared to normal cells (Herling et al., 2011). Metabolic changes occurring in 
cancer cells are considered to be fundamental for the transformation of normal cells into 
cancer cells and are also responsible for the resistance to different types of chemotherapeutic 
drugs (Cree, 2011). Therefore, resistance to chemotherapy represents a major problem in the 
treatment of several tumor types. Among the different metabolic and signalling pathways 
that are altered in cancer cells, variations in the expression and activity of several drug- 
metabolizing enzymes play a critical role in drug resistance (Rochat, 2009). Resistance can 
occur prior to drug treatment (primary or innate resistance) or may develop over time 
following exposure to the drug (acquired resistance). In some patients, prolonged exposure 
to a single chemotherapeutic agent may lead to the development of resistance to multiple 
other structurally unrelated compounds, known as cross resistance or multidrug resistance.  
Cancer cell metabolism is also closely linked to molecular oxygen concentration. Indeed, 
weak blood irrigation is frequently encountered in solid tumors and is responsible for 
hypoxic environment which is associated with invasive/aggressive phenotype and 
therapeutic resistance (Shannon et al., 2003). Hypoxia also contributes to drug resistance 
because some chemotherapeutic drugs require oxygen to generate free radicals that 
contribute to toxicity. Moreover, hypoxia might modulate expression of enzymes directly 
involved in metabolism of chemotherapeutic drugs, thereby limiting the toxic effects of 
these drugs on cancer cells. On the other hand, new therapeutic strategies aim at using 
bioreductive drugs that are selectively toxic to hypoxic cells (McKeown et al., 2007). 
The proposal of this chapter is to describe the role of anticancer drug metabolism in 
chemotherapy resistance but also its importance for the development of new approaches, 
taking advantage of the specificity of cancer cells metabolism. 
2. Anticancer drugs 
Anticancer or chemotherapy drugs are powerful chemicals that kill cancer cells by arresting 
their growth at one or more checkpoints in their cell cycle. Their main role is thus to reduce 
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and prevent the growth and spread of cancer cells. However, because anticancer agents 
rapidly affect dividing cells, normal cells are also affected. This is especially true in tissue 
with high cell turnover such as the gastrointestinal tract, bone marrow, skin, hair roots, 
nails... Consequently, side effects are commonly observed with various types of 
chemotherapies. More than 100 different drugs are used today for chemotherapy, either 
alone or in combination with other treatments.  
For several years, the most effective drugs used in cancer chemotherapy were DNA-
damaging agents (Gurova, 2009). These drugs can be divided into different categories based 
on their mechanism of action. Inhibitors of DNA synthesis inhibit essential biosynthetic 
processes or are incorporated into macromolecules (DNA and RNA). These drugs are either 
structural analogues for heterocyclic bases or agents interfering with folate metabolism 
(heterocyclic bases and folic acid are DNA building blocks) and they inhibit main steps in 
the formation of purine and pyrimidine bases as well as nucleotides (Parker, 2009). This 
class of agent includes antifolates (methotrexate, pemetrixed) (Goldman et al., 2010), 
antipyrimidines (5-fluorouracil, capecitabine, eniluracile, hydroxyurea) (Longley et al., 2003) 
and antipurines (6-mercaptopurine, 6-thioguanine). Another class of drugs directly damages 
DNA by adding methyl or other alkyl groups onto nucleotide bases (Izbicka and Tolcher, 
2004). This in turn inhibits their correct utilization by base pairing leading to mutation, DNA 
fragmentation as well as inhibition of DNA replication and transcription. These anticancer 
drugs include alkylating agents (cyclophosphamide, ifosfamide, melphalan, chlorambucil), 
platinum-based drugs (cisplatin, carboplatin), antibiotics (anthracyclines, dactinomycin, 
bleomycin, adriamycin, etoposide) and topoisomerase II inhibitors (camptothecine, 
irinotecan, topotecan). Molecules belonging to the third class affect synthesis or breakdown 
of the mitotic spindle (Risinger et al., 2009). These drugs disrupt the cell division by either 
inhibiting the tubulin polymerization and therefore the formation of the mitotic spindle 
(vinblastine, vincristine) or by stabilizing microtubules (paclitaxel, docetaxel).  
Over the past 20 years, the elucidation of different signal-transduction networks that are 
responsible for neoplastic transformation has led to rationally designed anticancer drugs 
that target specific molecular events. These targeted cancer drug candidates include protein 
kinase inhibitors that represent an important and still emerging class of therapeutic agents. 
Clinically approved kinase-targeted oncology agents include 1) small molecules such as 
imatinib (targeting Abl, Platelet-Derivated Growth Factor Receptor (PDGFR)), gefitinib and 
erlotinib (targeting epidermal growth factor Receptor (EGFR)), sorafenib (targeting PDGFR, 
EGFR, Raf-1, c-kit) or 2) antibodies such as Cetuximab or Bevacizumab that inhibit EGFR 
and vascular endothelial growth factor receptor (VEGFR), respectively (Sebolt-Leopold and 
English, 2006). Unfortunately, these new targeted drugs also face major obstacles similar to 
those that challenge traditional agents. 
3. Anticancer drug metabolism and resistance  
3.1 Anticancer drug metabolism 
In vivo, after absorption in the organism, xenobiotics (including anticancer drugs) are 
typically metabolized through a number of parallel and/or sequential reactions. Metabolism 
occurred through two distinct consecutive phases named “phase I” and “phase II”, although 
this order is not exclusive (phase I not always followed by phase II; phase II not always 
preceded by phase I) (Iyanagi, 2007). Phase I reactions are most commonly described as 
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“functionalization” reactions and include oxidations, reductions, and hydrolysis 
(Guengerich, 2007, 2008). These reactions introduce a new polar functional group to the 
parent drug (oxidation), modify an existing functional group in order to be more polar 
(reduction) or unmask existing polar functional group (hydrolysis). The most common 
functional groups exposed or introduced in the phase I reactions are hydroxyl (-OH), amino 
(-NH2), and carboxylic acid (-COOH).  
Phase II reactions are most commonly described as conjugation reactions and include 
glucuronidation, sulfonation, glycine/glutamine conjugation, acetylation, methylation, and 
glutathione (GSH) conjugation (Bock et al., 1987; Jancova et al., 2010). Conjugations allow 
linking a new group either to the parent drug or to phase I metabolites. Some conjugations 
cause a dramatic increase in the polarity and thus favor excretion of a drug by adding an 
ionized functional group: sulfonation, glucuronidation, and amino acid conjugation. Other 
conjugation reactions are just likely to cause termination of therapeutic activity: methylation 
and acetylation. GSH conjugation reaction protects against reactive metabolites.  
In this chapter, we will be interested mainly by two distinct families of enzymes, 
cytochrome P450s (CYP) and glutathione transferases (GST) belonging to phase I and phase 
II metabolism, respectively.  
3.1.1 Cytochrome P450s 
CYP enzymes are key players in the phase I-dependent metabolism, mostly catalyse 
oxidations of drugs and other xenobiotics. More than 57 active human CYP genes and 58 
pseudogenes have been described (Sim and Ingelman-Sundberg, 2010). Most of these genes 
are polymorphic and more than 434 different alleles of genes encoding CYP enzymes have 
been identified. The CYP3A (CYP belonging to family 3, subfamily A) enzymes are involved 
in the metabolism of about 50% of all drugs currently on the market (Bu, 2006). CYPs also 
participate in the metabolic activation of several carcinogens such as aflatoxin B1 (Langouet 
et al., 1995). As a result of the CYP-dependent metabolism, intermediates that exert toxicity 
or carcinogenicity can be formed. In most cases, these metabolites are targets for phase II 
enzyme dependent reactions, rendering them inactive polar products suitable for excretion 
via the kidneys. Concerning anticancer agents, CYPs are involved not only in cytotoxic 
drugs detoxication but also in the activation of prodrugs making them therapeutically 
effective (McFadyen et al., 2004). Prodrugs are inactive agents that are converted to active 
cytotoxic drugs upon exposure to tumor tissues exhibiting high expression of activating 
enzymes. This targeting strategy minimizes toxicity towards normal tissues while it 
increases delivery of active agent to the tumor tissue. Cyclophosphamide, ifosfamide, 
dacarbazine, procarbazine, tegafur, and thiotepa are metabolized by CYPs in the liver and 
this activation reaction is required for therapeutic activity (Rodriguez-Antona and 
Ingelman-Sundberg, 2006). Another example is 1,4-bis-([2-(dimethylamino-N-
oxide)ethyl]amino)5,8-dihydroxy anthracene-9,10-dione (AQ4N), a bioreductive prodrug 
that needs activation by CYP2S1 and CYP2W1 in tumor tissues to be converted to a 
topoisomerase II inhibitor (Nishida et al., 2010). Therefore, because CYPs are involved in 
either the bioactivation or the inactivation of both carcinogens and anticancer drugs 
(Huttunen et al., 2008), they play important roles in the etiology of cancer diseases and as 
determinants of cancer therapy (Oyama et al., 2004). 
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3.1.2 Glutathione transferases 
GSTs are a family of ubiquitous intracellular enzymes that catalyze the conjugation of GSH 
to many exogenous and endogenous compounds (Hayes et al., 2005). These include 
chemical carcinogens, therapeutic drugs and products of oxidative stress. In addition to 
their major role in catalyzing the conjugation of electrophilic substrates to GSH, these 
enzymes have GSH-dependent peroxidase (Hurst et al., 1998) and isomerase (Johansson and 
Mannervik, 2001) activities. GSTs play an important role in the protection against reactive 
molecules such as electrophilic xenobiotics (anticancer drugs, pollutants or carcinogens) or 
endogenous alpha,beta-unsaturated aldehydes, quinones, epoxides, and hydroperoxides 
formed as secondary metabolites during oxidative stress. Over the last decade, different 
studies have demonstrated that GSTs also have a non-catalytic function via their interaction 
with some kinases (Adler et al., 1999; Cho et al., 2001; Gilot et al., 2002) or other proteins 
(Dulhunty et al., 2001; Wu et al., 2006) thus playing critical roles in stress response, 
apoptosis and proliferation. GSTs are members of at least three gene families: the cytosolic 
(or soluble) GSTs that are divided in seven families: alpha, mu, pi, theta, sigma, zeta and 
omega (Hayes et al., 2005); the mitochondrial GST (kappa class) (Morel and Aninat, 2011) 
and the membrane-associated proteins involved in eicosanoid and glutathione metabolism 
(MAPEG) (Jakobsson et al., 2000; Jakobsson et al., 1999). The cancer chemotherapeutic 
agents adriamycin, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), busulfan, carmustine, 
chlorambucil, cisplatin, crotonyloxymethyl-2-cyclohexenone, cyclophosphamide, 
melphalan, mitozantrone and thiotepa are potent substrates of GSTs (Hamilton et al., 2003; 
Hayes and Pulford, 1995; Lien et al., 2002). Metabolism of these anticancer drugs by GSTs is 
related to several drug resistance phenomena and adverse toxicity effects (Townsend and 
Tew, 2003b).   
3.1.3 Drug transporters  
Drug passage across biological membranes is possible through two different mechanisms. 
The first one involves passive trans-cellular transport and concerned lipophilic molecules. 
The second one depends on carrier-mediated transporters, among which, we distinguish 
those requiring ATP-dependent hydrolysis as the first step in catalysis (ABC transporters 
such as multidrug resistance protein (MDR), multidrug resistance-associated protein (MRP), 
and breast cancer resistance protein (BCRP)) from those driven by an exchange or co-
transport of intracellular and/or extracellular ions with the substrate (organic anion 
transporter (OAT), organic anion-transporting polypeptide (OATP), sodium taurocholate 
co-transporting peptide (NTCP), organic cation transporter (OCT), novel organic cation 
transporter (OCTN) and oligopeptide transporter (PEPT)) (Keppler, 2011; Li et al., 2010; Ni 
et al., 2010; Svoboda et al., 2011).  
Active transporters are of great interest to pharmacologists since they are responsible for both 
the uptake and the efflux of drugs and are key elements of the pharmacokinetic characteristics 
of a drug (Degorter et al., 2011). Indeed, it has now become clear that transporters are essential 
for the uptake, accumulation, distribution and efflux of drugs. For example, drug efflux 
transporters including the P-glycoprotein pump (Pgp), the multidrug-resistant protein-1 
(MRP1) and the BCRP actively pump drugs such as chemotherapeutics out of the cells, thereby 
reducing their intracellular accumulation and making the cell insensitive to different drugs 
such as anthracyclines, vinca-alkaloids or taxanes. Among the major known ABC transporters, 
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ABCB1 gene, also known as MDR1, encoding Pgp is by far the best characterized and 
understood efflux transporter (Goda et al., 2009; Wu et al., 2011). It is predominantly expressed 
in several tissues including the luminal surface of intestinal epithelia, the renal proximal 
tubule, the bile canalicular membrane of hepatocytes and the blood brain barrier (Ho and Kim, 
2005). Pgp plays an important role in limiting intestinal drug absorption and brain penetration 
as well as in facilitating renal or biliary excretion of drugs. The MRPs are involved in the drug 
efflux from the liver or kidney into the peripheral blood (e.g. MRP1, MRP3, and MRP6), or 
from the liver, kidney and small intestines into the bile, urine and intestinal lumen respectively 
(MRP2) (Keppler, 2011). Since GSH-, glucuronide-, sulfate-conjugates and organic anions such 
as methotrexate, indinavir, cisplatin, vincristine and etoposide are all MRP substrates, MRPs 
are also crucial in human drug disposition and toxicity.  
3.2 Anticancer drug resistance 
The development of chemotherapy resistance remains a major problem to the effective 
treatment of many tumor types. Resistance can occur prior to drug treatment (primary or 
innate resistance) or may develop over time following exposure (acquired resistance). In 
some patients, prolonged exposure to a single chemotherapeutic agent may lead to the 
development of resistance to multiple other structurally unrelated compounds. This process 
is known as cross resistance or multidrug resistance (MDR). In primary resistance, MDR can 
occur without prior exposure to chemotherapy. Several mechanisms, including alterations 
in drug pharmacokinetic and metabolism, modification of drug target expression or 
function, drug compartmentalization in cellular organelles, altered repair of drug-induced 
DNA damages, changes in apoptotic signaling pathways or expression of proteins directly 
affecting cellular drug transport are responsible of anticancer drug resistance (Figure 1).  
 
Fig. 1. Representation of different mechanisms involved in anticancer drug resistance. 過: 
increase; 霞: decrease; OATP: organic anion-transporting polypeptide ; OCT : organic cation 
transporter ; Pgp: P-glycoprotein; MRP: multidrug resistance associated proteins; CYP: 
cytochrome P-450; SOD: superoxide dismutase; GST: glutathione transferase; MAPK: 
mitogen activated protein kinase. 
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3.2.1 Drug transport  
Drug transporters are the key determinants for the uptake, accumulation, distribution and 
efflux of several chemotherapeutic drugs. Interestingly, overexpression of these drug 
transporters in tumors has been demonstrated by several studies. Pgp is expressed in 
approximately 40% of all breast carcinomas (Trock et al., 1997), although another study 
reported values as high as 66% (Larkin et al., 2004). MRP3 was found to be the predominant 
MRP isoform in gallbladder carcinomas and cholangiocellular carcinomas and the intrinsic 
multidrug resistance in these carcinomas seems to be dependent on the expression of MRP3 
(Rau et al., 2008). The MRP4 (also named cMOAT or ABCC4) gene is overexpressed in 
cisplatin resistant human cancer cell lines with decreased drug accumulation (Taniguchi et 
al., 1996). Platinum-resistant tumor cells are capable of eliminating platinum GSH-
conjugates in an ATP-dependent manner through an active efflux mechanism mediated by a 
GS-X pumps (Ishikawa et al., 2000; Suzuki et al., 2001). MRP8, encoded by ABCC11 gene, is 
able to confer resistance to fluoropyrimidines by mediating the MgATP-dependent 
transport of the cytotoxic metabolite 5'-fluoro-2'-deoxyuridine monophosphate (Guo et al., 
2003). MRP2 expression has been suggested to affect the efficacy of cisplatin treatment in 
patients with hepatocellular carcinoma (Korita et al., 2010). Overexpression of these pumps 
in tumor cells gives them the ability to evade the treatment by drugs such as cisplatin, 
fluoropyrimidines, doxorubicin and etoposide in different types of cancer (Jedlitschky et al., 
1996; Kool et al., 1997; Xu et al., 2010; Zelcer et al., 2001). Therefore, the use of 
chemomodulators to inhibit efflux transport has been tested in an attempt to overcome this 
resistance (Baumert and Hilgeroth, 2009; Zhou et al., 2008). In this way, a recent study has 
demonstrated that indomethacin and SC236 inhibit Pgp and MRP1 expression and thus 
enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells (Ye et al., 
2011).  
3.2.2 Drug inactivation/detoxification  
Drug-metabolizing enzymes can also play an important role in reducing the intracellular 
concentration of drugs and in affecting cancer drug resistance. Interestingly, certain drugs 
require to be metabolized by these enzymes before exerting their cytotoxic effects. The 
expression of drug-metabolizing enzymes can therefore either potentiate or reduce the 
toxicity of chemicals and variations in both the activation and the inactivation pathways are 
important variables that can lead to drug resistance. In model systems, it appears that both 
oxidation (phase I) and conjugation (phase II) enzymes play critical roles in protecting cells 
against many drugs and thus play a key role in drug resistance.  
3.2.2.1 Involvement of cytochrome P450s 
As previously mentioned, CYPs are involved in both activation and detoxication of 
xenobiotics, including therapeutic drugs. CYP3A4 plays an important role in the metabolism 
of several anticancer agents (e.g. taxanes, vinca-alkaloids and new drugs such as imatinib, 
sorafenib and gefitinib). CYP3A4 metabolizes docetaxel to inactive hydroxylated 
derivatives. Therefore, a high CYP3A4 activity would result in a poor therapeutic outcome 
of the drug. Accordingly, in cancer patients treated with docetaxel in combination with the 
potent CYP3A4 inhibitor ketoconazole, a 49% decrease in docetaxel clearance was found 
(Engels et al., 2004). A low expression of CYP3A4 in breast tumors resulted in a better 
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response to docetaxel (Miyoshi et al., 2005). Similarly, hepatic CYP3A4 activity measured by 
the erythromycin breath test and midazolam clearance predicted docetaxel clearance and 
demonstrated a higher toxicity in patients with the lowest CYP3A4 activity (Goh et al., 
2002). Similarly to docetaxel, irinotecan is inactivated by CYP3A4 and induction of CYP3A4 
in patients receiving irinotecan results in a significant decrease in the formation of the toxic 
metabolite of this drug (Mathijssen et al., 2002). Additionally, CYP3A4 phenotype, as 
assessed by midazolam clearance, is significantly associated with irinotecan 
pharmacokinetic (Mathijssen et al., 2004). More recently, a study suggested that the 
Pregnane X-Receptor (PXR) pathway is also involved in irinotecan resistance in colon cancer 
cell line via the upregulation of drug-metabolizing genes such as CYP3A4 (Basseville et al., 
2011).  
Other CYP families also participate to anticancer drugs metabolism. For example, CYP2C19 
and CYP2B6 are involved in the activation of the chemotherapeutic agent 
cyclophosphamide (Helsby et al., 2010) and reduced expression of these CYPs is a potential 
mechanism of resistance. An interesting study showed a mechanism of acquired resistance 
to anticancer therapy based on the induction of CYP2C8 and MDR1. In this study, Caco-2 
cells were capable of increasing the expression of CYP2C8 as a response to long-term 
exposure to paclitaxel (Garcia-Martin et al., 2006). Furthermore, the correlation between 
CYP polymorphism and anticancer drug response has been demonstrated for CYP2B6. 
Indeed, CYP2B6*2, CYP2B6*8, CYP2B6*9, CYP2B6*4 variant alleles are associated with 
response to doxorubicin- cyclophosphamide therapy in the treatment of breast cancer and 
with a worse outcome (Bray et al., 2010). In another study, it has been demonstrated that 
CYP1B1 inactivates docetaxel and showed that the overexpression of CYP1B1 in a Chinese 
hamster ovary fibroblast cell line (V79MZ) was correlated to a significantly decreased 
sensitivity towards docetaxel (McFadyen et al., 2001a; McFadyen et al., 2001b). Finally, other 
authors suggested that CYP1B1 does not directly inactivate docetaxel but promotes cell 
survival by another unknown mechanism (Martinez et al., 2008).  
Altogether, these studies demonstrate that altered levels of expression or inhibition of CYPs 
can have profound effects on the sensitivity of target cell to toxic compounds.  
3.2.2.2 Involvement of glutathione transferases 
GSTs are involved in the development of resistance to anticancer drugs by different ways. 
Indeed, they play a role in the metabolism of a diverse array of cancer chemotherapeutic 
agents including adriamycin, BCNU, busulfan, carmustine, chlorambucil, cisplatin, 
cyclophosphamide, ethacrynic acid, melphalan or thiotepa (Chen and Waxman, 1994; 
Dirven et al., 1994; Paumi et al., 2001). The roles of GSTs in the metabolism of these 
anticancer drugs and the correlation between GST expression levels and drug sensitivity 
have been demonstrated in several studies. For example, the inhibition of GST Pi 1 (GSTP1) 
expression, through antisense cDNA, has been shown to increase the tumor sensitivity to 
adriamicin, cisplatin, melphalan and etoposide (Ban et al., 1996). By contrast, the 
overexpression of GSTP1 in human renal UOK130 tumor cells was accompanied by a 
decreased sensitivity to cisplatin, melphalan and chlorambucil (Wang et al., 2007). Similarly, 
overexpression of Alpha class GST has been correlated with the resistance to alkylating 
agents in Colo 320HSR cells (Xie et al., 2005) and to doxorubicin in MCF-7 human breast 
cancer and small cell lung cancer (H69) cell lines (Sharma et al., 2006; Wang et al., 1999). 
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Overexpression of Mu class GST has been associated with chlorambucil resistance in human 
ovarian carcinoma cell line (Horton et al., 1999) and with poor prognosis in childhood acute 
lymphoblastic leukaemia (Hall et al., 1994). 
Interestingly, high levels of GSTs are linked either with drug resistance or cancer incidence. 
GSTP1 has retained much attention because many tumors and cancer cell lines are 
characterized by high GSTP1 expression. Moreover, increased expression of GSTP1 has been 
associated to acquired resistance to cancer drugs (Tew, 1994). It is noteworthy that several 
studies have demonstrated that altered GST catalytic activities caused by genetic 
polymorphisms are linked to cancer susceptibility and prognosis (McIlwain et al., 2006). For 
example, GST genotypes are associated with primary and post-chemotherapy tumor 
histology in testicular germ cell tumors (Kraggerud et al., 2009); GST polymorphisms may 
have a role in treatment response and osteosarcoma progression (Salinas-Souza et al., 2010) 
and null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk (Wang 
et al., 2010). 
The non-catalytic functions of GST might also play a key role in the anticancer drug 
sensitivity. Indeed, the direct interaction and inhibition of various MAP Kinases by GSTs 
have been demonstrated. These MAP kinases are involved in cell proliferation and 
apoptosis but also in anticancer drug responses. In the last decade, several studies have 
demonstrated that GSTs are involved in the control of apoptosis through the inhibition of 
the Jun N-terminal Kinase (JNK) signaling pathway. Indeed, JNK is inactive and 
sequestered into a GSTP1-JNK complex (Adler et al., 1999) whereas Apoptosis Signal Kinase 
1 (ASK1) and Mitogen-activated protein kinase kinase kinase (MEKK1) interact with GSTM1 
leading to their inactivation (Gilot et al., 2002; Ryoo et al., 2004). Thus, the overexpression of 
GSTs in many tumors or their up-regulation by drugs could represent another mechanism 
of drug resistance, independent of their enzymatic activity. As an example, cisplatin, 
chlorambucil, doxorubicin, 5-fluorouracil and carboplatin are among anticancer drugs 
whose toxicity require the activation of JNK and resistance to these drugs is highly 
associated to overexpression of GSTs in tumors (Townsend and Tew, 2003a). Therefore, 
development of GST inhibitors that could prevent MAPK inhibition is considered as a 
promising strategy to achieve new anticancer drugs in order to increase chemotherapeutic 
efficiency. 
3.2.3 Involvement of nuclear transcription factors in drug resistance   
Nuclear receptors are a superfamily of transcription factors with 48 distinct members 
identified within the human genome (Germain et al., 2006). In addition to the classic 
steroidal hormone receptors, other nuclear receptors act as metabolic sensors that respond to 
compounds of dietary origin, intermediates in metabolic pathways, drugs and other 
environmental factors, integrating homeostatic control over many metabolic processes 
(Sonoda et al., 2008). For example, some aspects of drug metabolism and transport are 
regulated by pregnane X receptor (PXR) and constitutive androstane receptor (CAR); energy 
and glucose metabolism are regulated in part by peroxisome proliferator-activated receptor 
gamma (PPAR┛); fatty acid, triglyceride and lipoprotein metabolisms are controlled by 
PPAR┙, ├, and ┛; reverse cholesterol transport and cholesterol absorption depends on liver 
X receptor (LXR) activation and bile acid metabolism is regulated by farnesoid X receptor 
(FXR) (Evans, 2005; Francis et al., 2003).  
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PXR and CAR are master xenobiotic receptors that regulate the expression of genes involved 
in drug metabolism and clearance, including drug-metabolizing enzymes and transporters 
(Evans, 2005). In this part, we will focus on nuclear factors involved in the regulation drug-
metabolizing enzymes and drug transporters (PXR, CAR and Nrf2) and on their specific 
roles in drug resistance.  
3.2.3.1 Pregnane X receptor (PXR)  
In 1998, a new member of the nuclear hormone receptor family, named PXR (NR1I2), has 
been identified (Kliewer et al., 1998). PXR is activated primarily by pregnanes and dimerizes 
with retinoid X receptor (RXR) immediately after its activation by ligand binding. PXR is 
present in the cytoplasm where it interacts with a protein complex. After its activation, PXR 
translocates into the nucleus to regulate gene transcription (Squires et al., 2004). PXR 
recognizes a wide variety of ligands including dexamethasone, rifampicin, spironolactone 
and pregnenolone 16┙-carbonitrile being among the best characterized (Timsit and Negishi, 
2007) as well as many anticancer drugs such as microtubule-binding drugs (Raynal et al., 
2010). Targets genes of PXR are CYP3A4, MDR1, CYP2B6, members of UGTs superfamily 
and MRP3 and OATP2 transporters (Klaassen and Slitt, 2005; Tolson and Wang, 2010).¶ 
Due to its capacity to recognize such compounds and to induce transcription of genes 
involved in the detoxification process, PXR is considered as one of the master regulator of 
xenobiotic clearance. Moreover, because PXR controls the expression of key genes involved 
in anticancer drugs disposition, recent works have focused on its potential role in drug 
resistance (Chen, 2010). The mechanisms of resistance induced by PXR activation probably 
involve up-regulation of drug-detoxifying enzymes and transporters. Supporting this 
hypothesis, it has been shown that PXR activation by different ligands induces PXR target 
genes (CYP2B6, CYP3A4 and UGT1A1) and consequently drug resistance in ovarian cancer 
cells (Gupta et al., 2008). Moreover, PXR induces expression of CYP3A4 and MDR1 genes in 
multiple cell types and the products of these genes are known to detoxify microtubule-
binding and topoisomerase-binding drugs. Previous studies have shown that PXR activation 
regulates Pgp in the blood-brain barrier (Bauer et al., 2004). Interestingly, anticancer drugs 
such as vincristine, tamoxifen, vinblastine, docetaxel, cyclophosphamide, flutamide, 
ifosfamide and paclitaxel activate PXR-mediated Pgp induction and thus affect the cytotoxic 
activity and accumulation of the Pgp substrate  rhodamine 123 (Harmsen et al., 2010). 
Increased expression of PXR leads to higher resistance of HEC-1 cells to paclitaxel and 
cisplatin (Chen, 2010) and of human colon adenocarcinoma to doxorubicin (Harmsen et al., 
2010). In osteocarcinoma, the effectiveness of etoposide was reduced due to activation of 
PXR and the co-administration of PXR agonists enhanced the clearance of all-trans-retinoic 
acid (ATRA). This mechanism could potentially contribute to ATRA resistance in the 
treatment of acute promyelocytic leukemia (APL) and several solid tumors (Wang, T. et al., 
2008). However, other mechanisms of resistance (e.g., down-regulation of apoptotic genes) 
may also play a dominant role (Zhou et al., 2008). 
3.2.3.2 Constitutive androstane receptor (CAR)  
The constitutive androstane receptor (CAR) is a sister xenobiotic receptor of PXR. CAR 
was first purified from hepatocytes as a protein bound to the phenobarbital responsive 
element in the CYP2B gene promoter. CAR was subsequently shown to bind to the CYP2B 
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gene promoter as a heterodimer with retinoid X receptor (RXR). Transfected CAR 
exhibited a high basal activity and was once termed a “constitutively active receptor.” The 
name of constitutive androstane receptor was conceived due to the binding and inhibition 
of CAR activity by androstanes (Forman et al., 1998). CAR is retained in the cytoplasm by 
forming a complex with phosphatase 2A, HSP90 and cytosolic CAR retention protein 
(Kobayashi et al., 2003).  Phenobarbital, 5┚-pregnane-3,20-dione, and 5-androstan-3-ol are 
known CAR ligands (Moore et al., 2000). The hepatomitogen 1,4-Bis[2-(3,5-
dichloropyridyloxy)] benzene (TCPOBOP) is a synthetic agonist for murine CAR (Tzameli 
et al., 2000) and 6-(4-chlorophenyl)imidazo[2,1-b] [1,3]thiazole-5-carbaldehydeO-(3,4-
dichlorobenzyl)oxime (CITCO) is an imidazothiazole derivative that functions as a 
selective agonist for human CAR (Ikeda et al., 2005). Upon activation with specific 
agonist, CAR translocates into the nucleus and binds to the response elements as 
monomer or CAR/RXR heterodimer. CAR functions as a xenobiotic receptor that 
participates in the regulation of transcription of drug transporter genes such as MRPs 
(MRP2, MRP3 and MRP4), OATP2 and MDR1 ((Urquhart et al., 2007). CAR promotes the 
detoxification and elimination of potentially toxic compounds by modulating the phase I 
and phase II drug-metabolizing enzymes. Therefore, CAR-mediated expression of 
xenobiotic-metabolizing enzymes is generally protective, but can be deleterious if toxic 
metabolites are produced. CAR agonists are able to induce hepatocyte proliferation that 
depends on c-Myc-FoxM1 function (Blanco-Bose et al., 2008) but also to inhibit Fas-
induced hepatocyte apoptosis by depleting the proapoptotic proteins Bak (Bcl-2 
antagonistic killer) and Bax (Bcl-2-associated X protein) and increasing the expression of 
the antiapoptotic effector myeloid cell leukaemia factor-1 (Baskin-Bey et al., 2006).  
3.2.3.3 Nuclear factor-erythroid 2p45 (NF-E2)-related factor 2 (NRF2) 
The transcription factor Nrf2 (nuclear factor-erythroid 2p45 (NF-E2)-related factor 2) is a 
major regulator in the basal and inducible expression of various phase II detoxifying and 
antioxidant enzymes. In the resting state, kelch-like ECH-associated protein 1 (Keap1) 
functions as an intracellular redox receptor, which binds Nrf2 and targets it for proteosomal 
degradation. When cells are exposed to oxidative damage, Nrf2 is liberated from Keap1 and 
translocated into the nucleus where it specifically recognizes an enhancer sequence known 
as Antioxidant Response Element (ARE). This binding of Nrf2 on ARE sequence results in 
the activation of redox balancing genes (e.g. heme-oxygenase–1), phase II detoxifying genes 
(e.g. GSTs and NAD(P)H quinine oxidoreductase-1) and drug transporters (e.g. MRP) (Baird 
and Dinkova-Kostova, 2011; Taguchi et al., 2011). Several studies have suggested that the 
activation of Nrf2 protects against chronic diseases such as cardiovascular diseases, 
neurodegenerative disorders, lung inflammation, fibrosis, diabetes and nephropathy. 
However, in recent years, the dark side of Nrf2 has emerged and growing evidences suggest 
that Nrf2 constitutive up-regulation is associated with cancer development, progression and 
resistance to chemotherapy (Hayes and McMahon, 2006, 2009; Konstantinopoulos et al., 
2011; Wang X.J. et al., 2008). Many anticancer drugs are responsible for the production of 
ROS in cancer cells, a phenomenon which contributes to drug-induced apoptosis. Such 
species are scavenged by the catalytic activities of superoxide dismutase, catalase, GSH 
peroxidase, ┛-glutamylcysteine synthetase and heme oxygenase-1. These enzymes are 
members of the ARE-gene battery and are often overexpressed during carcinogenesis and it 
seems likely that Nrf2 may be responsible for this phenotype. 
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The down-regulation of Nrf2-dependent response by overexpression of its negative 
regulator, Keap1, or transient-transfection of Nrf2-siRNA in lung carcinoma, breast 
adenocarcinoma, neuroblastoma, ovarian cancer and colon cancer rendered cancer cells 
more susceptible to cisplatin, etoposide, doxorubicin and 5-fluorouracil (Akhdar et al., 2009; 
Cho et al., 2008; Homma et al., 2009; Wang, X.J. et al., 2008). Induction of nuclear 
translocation and activation of Nrf2 by 5-fluorouracil, which in turn leads to antioxidant 
enzymes up-regulation and increases resistance toward cytotoxic effects of this anticancer 
drug has been recently demonstrated (Akhdar et al., 2009). The inhibition of Nrf2 by a 
specific flavone, lutolein, leads to negative regulation of the Nrf2/ARE pathway and to the 
sensitization of human lung carcinoma cells to therapeutic drugs (Tang et al., 2011). KEAP1 
gene deletion provoked an aberrant Nrf2 activation and is one of the molecular mechanisms 
explaining chemotherapeutic resistance against 5-FU in gallbladder cells (Shibata et al., 
2008a; Shibata et al., 2008b). Several studies have reported mutations of the interacting 
domain between Keap1 and Nrf2 leading to a permanent Nrf2 activation in non-small cell 
lung cancer (Ohta et al., 2008; Padmanabhan et al., 2006). Somatic mutations of the KEAP1 
gene were also reported in patients affected by gall bladder tumors and in breast cancer cell 
line (Nioi and Nguyen, 2007; Shibata et al., 2008a). Although recent studies demonstrated 
low or no expression of KEAP1 in more than half of non-small cell lung cancers, only two 
papers investigated the epigenetic alterations of KEAP1 in this type of tumor. An aberrant 
hypermethylation at the KEAP1 gene promoter in lung cancer cell lines and in five lung 
cancer tissues has been demonstrated (Wang, R. et al., 2008). More recently, two alterations 
in KEAP1 gene were detected in one third of the non-small cell lung cancers suggesting that 
both copies of the gene might be inactivated (Muscarella et al., 2011). In these cases, Keap1 
function is impaired, leading to constitutive stabilization of Nrf2 and increased activation of 
its cytoprotective target genes (Okawa et al., 2006).  
All of these findings support the idea that increased Nrf2 expression could facilitate cell 
growth, survival, resistance to chemotherapy through the activation of cytoprotective 
factors. Thus, investigating the deregulation of Keap1/Nrf2 pathway may shed light into 
the understanding of molecular mechanism of chemoresistance. 
3.2.3.4 Hypoxia and Hypoxia Inducible Factor-1 (HIF-1)  
Hypoxia and HIF-1α are found in solid tumors  
Around fifty percent of locally advanced solid tumors exhibit hypoxic and/or anoxic tissue 
areas, heterogeneously distributed within the mass tumors (Vaupel and Mayer, 2007). 
Consequently, partial pressure of oxygen (PO2) in tumors is variable and can reach values 
between 10 to 30 mmHg (equivalent to 1 to 3% O2), in contrast to a PO2 of 50–80 mmHg in 
most normal tissues (Grigoryan et al., 2005). Three converging mechanisms lead to this 
limited oxygenation in cancer cells. The first one is due to cell proliferation which is 
responsible for an increase of the tumor mass. The second one is characterized by a loss of 
structural organization of blood vessels already present or newly formed (angiogenesis) in 
the solid tumor. This process leads to a decreased irrigation of the tumor. In addition, 
hematologic status of patients with cancer is frequently modified by the disease itself or by 
chemotherapy and numbers of them suffer from anemia triggering a reduced oxygen-
carrying capacity of the blood (Vaupel and Harrison, 2004; Vaupel and Mayer, 2007). HIF-1 
transcription factor is a master regulator of the hypoxic response and HIF-1α subunit is 
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stabilized during hypoxia. Therefore, overexpression of HIF-1α has been found in many 
human cancers such as bladder, brain, breast, colon, ovarian, pancreatic, prostate and renal 
carcinomas (Talks et al., 2000). 
Metabolic adaptation to hypoxia and angiogenesis in solid tumor: HIF-1 and HIF-target genes 
In order to fight against hypoxia, a metabolic adaptation of solid tumors is observed 
compared to the surrounding normal tissue. This phenomena has been first described by 
Otto Warburg (Warburg, 1956) fifty years ago. He found that, in contrast to normal tissue 
where glycolysis is used to produce approximately 10% of ATP (the remaining 90% being 
obtained by oxidative phosphorylation via the tricarboxylic acid (TCA) cycle); solid tumors 
produced over 50% of ATP by anaerobic glycolysis, i.e. without oxidative phosphorylation 
and with lactate production. Interestingly, this phenomenon occurs even if oxygen is 
available for the mitochondrial function. This altered energy dependency is known as the 
“Warburg effect” and is a hallmark of cancer cells. Several explanations have been given to 
understand the use of anaerobic glycolysis rather than oxidative phosphorylation for 
production of ATP, while this is less efficient for energy production. The first one is linked 
to the accumulation of mutations in the mitochondrial genome that prevent the proper 
functioning of mitochondria (Carew and Huang, 2002). As a consequence, oxidative 
phosphorylation is not enough efficient, forcing the cancer cells to use anaerobic glycolysis 
for ATP production. The second one involves the activation of a transcription factor 
specifically activated in cell response to hypoxia: the transcription factor hypoxia-inducible 
factor-1 (HIF-1).  
HIF-1 transcription factor is composed of two protein subunits, HIF-1α and HIF-1β (Wang 
and Semenza, 1995). Its transcriptional activity depends on the stabilization of HIF-1α. 
While HIF-1β subunit is constitutively expressed into the cells, expression of HIF-1α protein 
is thinly regulated at a post-translational level. Hydroxylation of HIF-1α by prolyl 
hydroxylase domain (PHD) proteins, which target its subsequent proteasomal degradation, 
is one of the major mechanisms of regulation of HIF-1α cellular levels (Jaakkola et al., 2001). 
Since the activity of PHD enzymes is inhibited by low oxygen tension, HIF-1α protein is 
stabilized during hypoxia. As a result, upon hypoxic signal, HIF-1α subunit is stabilized 
translocated into the nucleus where it binds to HIF-1β to form the active HIF-1 complex. 
HIF-1 binds to hypoxia-responsive elements (HRE), consensus sequences in the promoter 
region of more than one hundred genes involved in cell proliferation, differentiation and 
survival, angiogenesis and energy metabolism that allow the cell, tissue, and organism to 
adapt to reduced oxygen conditions (Semenza, 2003).  
Regarding glycolysis metabolism, several HIF-1 gene targets are directly involved in the 
switch between aerobic to anaerobic glycolysis. Glucose cell uptake and its metabolism are 
very active in cancer cells. This high activity is correlated with the induction of expression of 
both the glucose transporter GLUT1 and the glycolysis enzymes aldolase C and 
phosphoglycerate kinase 1 (PGK1) (Seagroves et al., 2001; Semenza, 2003). Furthermore, 
HIF-1 facilitates the conversion of pyruvate into lactic acid by the induction of lactate 
dehydrogenase A (LDHA) (Firth et al., 1995) and pyruvate dehydrogenase kinase 1 (PDK1) 
expressions (Kim et al., 2006; Papandreou et al., 2006). PDK1, by inhibiting the activity of the 
pyruvate dehydrogenase (PDH) (Patel and Korotchkina, 2001), prevents conversion of 
pyruvate into acetyl-CoA, promotes the conversion of pyruvate into lactate and reduces the 
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metabolic activities of the TCA cycle and the mitochondrial oxidative phosphorylation. 
Finally, in order to prevent acidosis due to lactate accumulation, intracellular pH 
homeostasis is maintained by induction of the expression of the carbonic anhydrase 9 and 12 
(CA9 and CA12) (Potter and Harris, 2004), the lactate transporter MCT-4 (Ullah et al., 2006) 
and the Na+/H+ exchanger NHE1 (Shimoda et al., 2006), all direct gene targets of HIF-1. 
Thus, those metabolic adaptations confer a selective growth advantage and, combined with 
angiogenesis, are a prerequisite for metastasis.  
HIF-1 also plays a key role in angiogenesis, which is a process describing the growth of new 
blood vessels (neovascularization) from preexisting vessels. Angiogenesis is critical for 
tumor development since supply of oxygen and nutriments becomes limited to cancer cells 
located around 70-100 microns of a blood vessel (Carmeliet and Jain, 2000). Ability of tumor 
cells to induce angiogenesis occurs by a multi-step process, regulated by many pro-
angiogenic factors. One of the strongest stimuli of angiogenesis is hypoxia and its 
transcription factor HIF-1 (Pugh and Ratcliffe, 2003). Indeed, HIF-1 can directly induce the 
expression of a number of proangiogenic factors such as the vascular endothelial growth 
factor (VEGF) and its receptors VEGFR1 and VEGFR2, the angiopoietins (ANG-1 and -2) 
and their receptors (Tie-1 and Tie-2) and the platelet-derived growth factor PDGF-┚ (Hickey 
and Simon, 2006). Of all the pro-angiogenic factors induced by HIF-1, VEGF is the factor that 
is most expressed in tumors (Dvorak, 2002). In several in vitro and in vivo models, HIF-1 
signaling is required for VEGF production and the ability of tumor cells to promote 
angiogenesis. As such, stem cells HIF-1┙-/- injected into nude mice form teratocarcinomas 
substantially smaller and less vascularized than WT embryonic cells (Ryan et al., 1998). 
HIF-1 and HIF-target genes: Actors for drug resistance 
Hypoxia and HIF-1 contribute to the poor response to anticancer therapy by several 
mechanisms (Cosse and Michiels, 2008; Tredan et al., 2007; Wouters et al., 2007). Indeed, 
HIF-1 activation allows expression of a battery of genes involved in survival and cell 
resistance to chemotherapy. For examples, studies have shown that hypoxia is directly 
involved in the induction of genes coding for the ABC transporters (MDR1, MRP1 and LRP), 
responsible for HepG2 cells resistance toward 5-Fluorouracil (Comerford et al., 2002; Zhu et 
al., 2005). Moreover, a recent study has demonstrated that, by down-regulating the 
expression of the MAPK-specific phosphatase dual-specificity phosphatase–2 (DUSP2), HIF-
1 is involved in the resistance of HeLa and HCT116 cells to cisplatin, oxaliplatin, and 
paclitaxel (Lin et al., 2011). Hypoxia, by modulating expression of enzymes directly 
involved in metabolism of chemotherapeutic drugs, such as CYPs, could also limit the toxic 
effects of these drugs on cancer cells. As such, paclitaxel metabolism into 6α-
hydroxypaclitaxel is reduced upon hypoxic conditions compared to normoxic conditions in 
HepaRG cells (Legendre et al., 2009). Furthermore, cytotoxic anticancer drugs require the 
presence of oxygen to exert their effects via the production of ROS, damaging DNA and 
inducing cell cycle arrest and death by apoptosis. Therefore, lack of oxygen could interfere 
for the efficiency of those molecules such as doxorubicin, which exerts its cytotoxic effect by 
the production of superoxide anion (Grigoryan et al., 2005). Another important point is that 
solid tumors are often poorly irrigated, leading to a decreased accessibility of anticancer 
agents to the tumor. Decreased drug concentrations, because of limited drug penetration 
into tumor masses, participates actively to resistance of the tumor to chemotherapy (Tredan 
et al., 2007). Finally, hypoxic environment of solid tumors is often correlated with a decrease 
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of extracellular pH (acidosis) that also modulates the accumulation and/or cell toxicity of 
anticancer agents (Gerweck, 1998; Reichert et al., 2002). For example, resistance to 
mitoxantrone in MCF-7 cells is related to the acidification of extracellular pH (Greijer et al., 
2005). Taken together, hypoxia and HIF-1 play a key role in anticancer drug resistance. 
3.2.4 Other mechanisms 
Modification of drug target  
Cells survival depends on a balanced assembly and disassembly of the highly conserved 
cytoskeletal filaments formed from actin and tubulin. Microtubules are assembled from ┙-
tubulin and ┚-tubulin heterodimers, along with other proteins such as microtubule-
associated proteins. Some anticancer drugs (such as vinca-alkaloids) bind to and stabilize 
free tubulin, causing microtubule depolymerization and others (such as taxanes) bind to and 
stabilize microtubules, causing a net increase in tubulin polymerization (Zhou and 
Giannakakou, 2005). These two mechanisms of action inhibit cell division and thereby 
trigger apoptosis of cells. Altered expression of ┚-tubulin isotypes (overexpression or 
mutation) and microtubule-associated proteins is found in many cancer cell lines and 
xenografts resistant to microtubule inhibitors. These alterations may be associated with the 
primary or acquired resistance to tubulin-binding agents observed clinically in many tumors 
(Kamath et al., 2005; Wang and Cabral, 2005). Recently, a novel skeleton microtubule 
inhibitor, chamaecypanone C, with anticancer activity triggering caspase 8-Fas/FasL 
dependent apoptotic pathway in human cancer cells has been identified and its cytotoxicity 
in a variety human tumor cell lines has been studied (Hsieh et al., 2010). The authors 
considered that chamaecypanone C is a promising anticancer compound that has potential 
for management of various malignancies, particularly for patients with drug resistance. 
DNA repair and cellular damages 
Many anticancer drugs exert their effects by inducing DNA damages. Thus, alterations in 
enzymes involved in DNA repair can affect drug resistance. Topoisomerase II is a critical 
enzyme that is involved in DNA replication and repair and reduced topoisomerase II 
expression or function can contribute to resistance to agents such as anthracyclines (Nitiss, 
2009). DNA mismatch repair mediates damage repair from many drugs including alkylating 
agents, platinum compounds and anthracyclines and this mechanism has been implicated in 
drug resistance in cancer cells (Bignami et al., 2003).  
Apoptosis  
Resistance can also arise from a failure of the cells to undergo apoptosis following DNA 
damages or other cellular injuries. Alterations in genes regulating the apoptotic pathway 
such as BCL2, BCLX (anti-apoptotic proteins) or TP53 promote resistance to anticancer drugs 
(O'Connor et al., 1997). P53 can trigger elimination of the damaged cells by promoting 
apoptosis through the induction of pro-apoptotic genes, such as FAS and BAX, and the 
down-regulation of anti-apoptotic BCL2. Studies have reported that loss of p53 function 
reduces cellular sensitivity to anticancer drugs. Mutations in the TP53 gene are found in 
most human breast cancer cell lines, and certain mutations have been linked to de novo 
resistance to doxorubicin (Aas et al., 1996). On the other hand, the use of adenovirus-
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4. Taking advantage of cancer cell metabolism for drug targeting 
4.1 Nuclear factors: Targets for new therapeutic strategies 
4.1.1 PXR and CAR 
During the last years, several groups have studied the role of PXR antagonists as potential 
pharmaceuticals for the reversal of drug resistance and enhancement of drug delivery 
(Biswas et al., 2009; Harmsen et al., 2010). Ketoconazole was originally described as a PXR 
antagonist (Takeshita et al., 2002). However, significant side effects of ketoconazole were 
reported mainly because of its off-target effects (e.g., cortisol synthesis, hepatic toxicity), 
some of which are related to its capacity to inhibit CYP activities. Recently, the development 
and characterization of a first-in-class novel azole analog [1-(4-(4-(((2R,4S)-2-(2,4-
difluorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethanone (FLB- 
12)] that antagonizes the activated state of PXR has been published (Venkatesh et al., 2011). 
This analog has limited effects on other related nuclear receptors LXR, FXR, estrogen 
receptor ┙, PPAR┛, and mouse CAR. FLB-12 was demonstrated to abrogate endogenous 
PXR activation in vitro and in vivo and was less toxic to liver cells in vivo compared to 
ketoconazole. Interestingly, FLB-12 significantly abrogates PXR-mediated resistance to 7-
ethyl-10-hydroxycamptothecin (SN-38) in colon cancer cells in vitro. These drugs will not 
only serve as valuable chemical tools for probing PXR action but will also be important 
adjuncts for novel targeted approaches against cancer drug resistance.  
Thus, the concept that down-regulating PXR can sensitize cancer cells to chemotherapeutic 
agents has been proposed and investigated in several studies. In the prostate cancer cell line 
PC-3, treatment with the PXR agonist SR12813 activates PXR and increases both the 
expression of MDR1 and the resistance of PC-3 cells to the anticancer drugs paclitaxel and 
vinblastine. Inversely, the targeted knock-down of PXR by using short hairpin RNA 
(shRNA) enhanced the sensitivity of PC-3 to paclitaxel and vinblastine, suggesting that the 
effectiveness of anticancer drugs can be enhanced in PXR-positive cancers by decreasing the 
expression of PXR. Down-regulation of PXR by small interfering RNA (siRNA) in the 
endometrial cancer cell line HEC-1 also decreased the expression of MDR1 and sensitized 
cells to anticancer agent and PXR agonist paclitaxel and cisplatin (Masuyama et al., 2003; 
Masuyama et al., 2007). Other reports suggest that down-regulation of PXR may contribute 
to apoptotic and drug sensitivity in cancer cells (Gong et al., 2006; Masuyama et al., 2007). 
Finally, expression of PXR in human colorectal cancer cells led to irinotecan chemoresistance 
through enhancement of its glucuronidation catalyzed by UGT1A1. The opposite effect was 
obtained with pharmacological inactivation of PXR or shRNA-mediated PXR down-
regulation, confirming the direct involvement of PXR in irinotecan chemoresistance (Raynal 
et al., 2010). Altogether, these studies demonstrate that PXR represents a potential 
therapeutic target for clinical applications relevant drug resistance. 
Although the properties of CAR and its agonists in xenobiotic metabolism have been 
extensively studied, its anticancer property was not known until very recently. Indeed, a 
recent study showed that CAR is a positive regulator of MDR1 (Pgp), MRP2 and BCRP 
expression in rat and mouse brain capillaries (Wang, B. et al., 2010). Moreover, another 
study demonstrated that CITCO inhibits the growth and expansion of brain tumor cancer 
stem cells by inducing cell cycle arrest and apoptosis in vitro (Chakraborty et al., 2011). 
Although the CAR-mediated antineoplastic effect is not known, these results support the 
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use of CAR agonists as a new therapy to target brain tumor cancer stem cells for the 
treatment of glioma.  
4.1.2 HIF-1 and its target genes 
The adaptive cellular response of cancer cells to hypoxia offers new pharmacological targets, 
including the central regulator of molecular and cellular response to hypoxia HIF-1 as well 
as some of its target genes, particularly the VEGF and the carbonic CA9 (see Table 1). 
Validation of HIF-1 as a therapeutic target has been based on studies using genetic 
manipulation. When HIF-1α expression is increased in human cancer cells, angiogenesis 
capacity and metastasis spread are observed. Conversely, inhibition of the HIF-1α 
expression reverses those effects (Semenza, 2007). Accordingly, injection of tumor cells 
overexpressing HIF-1α into immunodeficient mice has demonstrated the capacity of HIF-1 
to promote tumorigenesis (Maxwell et al., 1997).  A growing number of novel anticancer 
agents have been shown to inhibit HIF-1 through a variety of molecular mechanisms. One of 
these promising molecules, the YC-1 ((3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole), 
decreases the levels of HIF-1α protein through inhibition of the PI3K/AKT/mTor pathway 
(Sun et al., 2007). It has been shown that inhibition of HIF-1α activity in tumors from YC-1-
treated mice is associated with blocked angiogenesis and an inhibition of tumor growth 
(Yeo et al., 2003).  
 
Target Agent Mechanism of action 
Hypoxia Mitomycin C DNA damages 
 Banoxantrone (AQ4N) DNA damages and topoisomerase II inhibitor 
 Tirapazamine (TPZ) DNA damages 
HIF-1 pathway  YC-1a PI3K/AKT/mTor inhibitor 
 Tanespimycin (17-AAG) HSP90 inhibitor 
 PX-12b Thioredoxin inhibitor 




CA9 CAI17  CA9-specific small molecule inhibitor  
VEGF Sorafenib Tyrosine kinase inhibitor 
 Bevacizumab Anti-VEGF antibody 
GLUT1 Fasentin 
Interacts with GLUT1 transporter and block 
glucose uptake 
Table 1. Examples of pharmacological approaches to target hypoxic cancer cells. a 3-(5'-
Hydroxymethyl-2'-furyl)-1-benzylindazole; b 1-methylpropyl 2-imidazolyl disulfide. 
Angiogenesis has been described as one of the hallmarks of cancer, playing an essential role 
in tumor growth, invasion, and metastasis. For this reason, inhibition of angiogenesis has 
become a major challenge in the development of new anticancer agents, particularly in 
targeting the VEGF pathway. Sorafenib, a multitargeted inhibitor of tyrosine kinase,  
inhibits the receptor tyrosine kinase VEGFR2 and PDGFR and the Ras/Raf pathway 
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(Keating and Santoro, 2009). Currently, this anticancer molecule demonstrated encouraging 
result for palliative therapy and can prolong the overall survival for patients with advanced 
hepatocellular carcinoma (Cheng et al., 2009). Moreover, anti-angiogenic therapy seems 
efficient to improve survival from patients with hepatocellular carcinoma and the anti-
VEGF monoclonal antibody bevacizumab has shown promising results (Llovet and Bruix, 
2008).  
Increased expression of CA9 has been found in many cancers and has been associated to an 
unfavorable prognosis (Kaluz et al., 2009; Pastorekova et al., 2008; Potter and Harris, 2004). 
Silencing both CA9 and CA12 resulted in marked inhibition of the growth of LS174 human 
colon carcinoma cell xenograft tumors (Chiche et al., 2010). Therefore, CA9 seems to be a 
new candidate for the development of new anticancer strategy. Interestingly, novel CA9-
specific small molecule inhibitors such as the sulfonamide-based CAIX inhibitor CAI17 
resulted in significant inhibition of tumor growth and metastasis formation in both 
spontaneous and experimental models of metastasis. 
4.2 Bioreductive agents 
It has been suggested that hypoxic environment in tumor tissues could be used as an 
advantage to target cancer cells with prodrugs that are metabolized into toxic metabolites 
only in hypoxic areas (McKeown et al., 2007). These drugs, also named bioreductive agents, 
are divided into 4 groups: quinones, nitroaromatics or nitro-heterocyclic, aliphatic N-oxides 
and heteroaromatic N-oxides. 
Mitomycin C that belongs to the quinone family is an alkylating antineoplastic agent and is 
frequently used for chemoembolization therapy. Bioreduction and activation of mitomycin 
C are facilitated upon a hypoxic environment. Indeed, electrons gain (reduction) of 
mitomycin products a semiquinone radical anion, which forms a covalent interaction with 
DNA. In the presence of oxygen, this radical anion is quickly degraded, thus giving the 
selectivity of hypoxia for generation of cytotoxic species (Kennedy et al., 1980).  
AQ4N or banoxantrone, is part of the aliphatic N-oxides. AQ4N is reduced into AQ4 under 
hypoxic condition. AQ4 exerts its cytotoxic activity by binding DNA and acting as an 
inhibitor of topoisomerase II. Used in combination with other anticancer agents, it has anti-
proliferative effects on tumor cells (Patterson and McKeown, 2000). 
4.3 Activation of prodrugs by glutathione transferases 
As previously mentioned, a feature of cancer cell is to overexpress certain drug-
metabolizing enzymes and transporters.  Pathways involving such proteins that are 
aberrantly expressed in cancer cells are preferentially targeted for drug intervention. For 
example, the enhanced expression of GSTP1 in several tumors makes this protein a 
promising target for prodrug therapy. In order to take advantage of GSTP1 overexpression 
in cancer cells, two strategies have been performed. The first one consists in designing and 
developing inhibitors of GSTP1. Initially, this strategy was developed in order to decrease 
the metabolism of several active anticancer drugs known to be inactivated by GST. 
Furthermore, in 1999, evidence for a direct interaction of mouse GST pi with JNK was 
demonstrated (Adler et al., 1999). Their work showed that, under a monomeric state, GST pi 
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acts as a direct JNK inhibitor in non-stressed cells by forming a complex with JNK and c-Jun. 
Oxidative stress (UV, H2O2…) induces the dimerization of GST pi and activation of c-jun 
through its phosphorylation on Ser-63 and Ser-73 residues. Subsequently, several other 
studies have corroborated this model in other cell lines (Bernardini et al., 2000; Castro-
Caldas et al., 2009) and have shown that overexpression of GSTP1 in several tumor tissues 
lead to an inhibition of apoptosis pathways. Thus, inhibitor of GSTP1 triggering the 
disruption of this interaction could induce apoptosis in the cancer cell. TLK199 is one of 
them (Raza et al., 2009). The second strategy consists in designing prodrug activated by this 
enzyme in order to target specifically the tumor cells overexpressing GSTP1. Thus, novel 
alkylating agents have been synthetized (Lyttle et al., 1994; Satyam et al., 1996). Cleavage of 
these molecules by GSTP1 lead to the release of two metabolites: an inactive GSH conjugate 
and a phosphorodiamide compound. The phosphorodiamide spontaneously gives an 
alkylating moiety (a nitrogen mustard alkylating agent) which is responsible for the 
cytotoxicity. Among all the products synthetized, one has been actively studied and is tested 
in phase 2 and 3 studies (Kavanagh et al., 2010; Vergote et al., 2009). Initially named TER286, 
then TLK286, it is now designate with the International Nonproprietary Name (INN) 
canfosfamide (Telcita®). Several in vitro and in vivo studies, either on cell lines or on 
xenograft models, have linked the cytotoxicity of this molecule with the high level 
expression of GSTP1 and the formation of the alkylating moiety (Izbicka et al., 1997; Morgan 
et al., 1998; Rosario et al., 2000). Furthermore, Townsend et al. (Townsend et al., 2002) have 
demonstrated that canfosfamide is able to inhibit an enzyme involved in double strand 
break DNA repair, the DNA-dependent protein-kinase (DNA-PK). Interestingly, up-
regulation of this DNA-PK leads to a resistance of adriamycin and cisplatin, suggesting that 
canfosfamide could be used in combination with these drugs. Several phase I studies have 
been realized in order to determine the safety and the pharmacokinetic of canfosfamide in 
human. These tests have been performed in advanced refractory solid cancers and have 
shown that canfosfamide is well tolerated with mild or moderate adverse effects such as 
nausea, vomiting, fatigue and anemia (grade 1 or 2) (Rosen et al., 2003; Rosen et al., 2004). 
Furthermore canfosfamide seems to be active in a large range of cancer including advanced 
non-small cell lung tumor (Sequist et al., 2009). Phase 2 and 3 clinical studies have also been 
done on resistant epithelial ovarian cancer (Kavanagh et al., 2010; Vergote et al., 2009). 
Another family of compounds is under development. These compounds own an O2-aryl 
diazeniumdiolate structure and are also metabolized by GSTP1 in a non-stable metabolite 
owning a Meisenheimer complex intermediate, which gives a GSH metabolite (PABA-GSH) 
and nitrogen monoxide (NO). Several of them have been designed (Andrei et al., 2008; 
Chakrapani et al., 2008; Saavedra et al., 2006) but the most specific and the most studied is the 
PABA/NO (O2-[2,4-dinitro-5-(p-methylaminobenzoato)] 1-(N, N-dimethylamino)diazen-1-
ium-1,2-diolate) (Ji et al., 2008). Antiproliferative proprieties have been observed in several cell 
lines, including the mouse skin fibroblast NIH3T3 (Findlay et al., 2004), the human 
promyelocytic leukemia HL60 (Hutchens et al., 2010), the human leukemia U-937, the non-
small-cell lung cancer H441, the colon cancer (HCT-116, HCT-15 and HT-29), the ovarian 
cancer OVCAR-3 (Andrei et al., 2008) and the U87 gliomas cell lines (Kogias et al., 2011). 
Antitumor activity was also demonstrated in an A2780 human ovarian cancer xenograft model 
in female SCID mice (Findlay et al., 2004). Mechanisms of cytotoxicity of PABA/NO involve 
several pathways which are due to the NO production and the nitrosylation and S-
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glutathionylation of some proteins. Townsend et al. (2005) have shown that PABA/NO is able 
to induce S-glutathionylation of several proteins, including the protein disulfide isomerase 
(PDI) (Townsend et al., 2005). Glutathionylation of PDI triggers a decrease of the folding 
protein capacity response, leading to cytotoxic effects. Activation of the apoptosis pathway 
through activation of JNK and p38 has also been observed (Townsend et al., 2005). 
Furthermore, GSH metabolite of PABA/NO is also able to inhibit sarco/endoplasmic 
reticulum calcium ATPases iso-enzymes, leading to an intracellular Ca2+ increase, triggering 
activation of the calmodulin pathway and thus increasing production of NO by endothelial 
Nitric Oxide Synthase (Manevich et al., 2010). 
5. Conclusion 
During the last years, several mechanisms involved in resistance phenomena have been 
elucidated and showed that, in many cases, drug-metabolizing enzymes and drug 
transporters are key factors in the failure of cancer therapies. In some cases, these 
discoveries led to useful strategies to identify “sensitive” tumors and direct clinical 
decisions for the choice of therapy. Furthermore, the molecular classification of several 
tumor types based on genome-wide investigations and identification of patient subclasses 
according to drug responsiveness should help to propose a more personalized medicine and 
to overcome anticancer drug resistance. Another promising field of investigation is to take 
advantage of cancer cell specificity in order to develop new tumor-targeted approaches that 
afford tumor specificity and limited toxicity. 
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